Glucotrack, Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
GCTK$1.39-32.2%Stored close · as of Oct 29, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statement of Changes in Stockholders’ Equity
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)
(in thousands of US Dollars except share data) (unaudited)
| In thousands of US Dollars (except share data) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Common Stock · Receipts · Accumulated | ||||||||
| Numbers of Shares · Amount · Additional Paid-in Capital · on account of shares · Other Comprehensive Income · Accumulated Deficit · Total Stockholders’ Equity | ||||||||
| Balance as of December 31, 2025 | 910,688 | $1 | $151,080 | $3,544 | $41 | $(151,838) | $2,828 | |
| Loss for the period | - | - | - | - | - | (4,334) | (4,334) | |
| Other comprehensive income | - | - | - | - | 3 | - | 3 | |
| Stock-based compensation | - | - | 61 | - | - | - | 61 | |
| Issuance of common stock upon exercise of pre-funded warrants | 1,033,591 | 1 | 3,544 | (3,544) | - | - | 1 | |
| Issuance of common stock upon completion of ELOC financing, net of offering expenses | 580,000 | 1 | 589 | - | - | - | 590 | |
| Balance as of March 31, 2026 (Unaudited) | 2,524,279 | $3 | $155,274 | $ | - | $44 | $(156,172) | $(851) |
| In thousands of US Dollars (except share data) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Common Stock · Receipts · Accumulated | ||||||||
| Numbers of Shares · Amount · Additional Paid-in Capital · on account of shares · Other Comprehensive Income · Accumulated Deficit · Total Stockholders’ Equity | ||||||||
| Balance as of December 31, 2024 | 13,193 | $ | -* | $119,230 | $228 | $(8) | $(132,450) | $(13,000) |
| Loss for the period | - | - | - | - | - | (6,833) | (6,833) | |
| Other comprehensive income | - | - | - | - | 36 | - | 36 | |
| Stock-based compensation | - | - | 40 | - | - | - | 40 | |
| Issuance of common stock upon completion of public offering, net of offering expenses | 250,267 | -* | 6,394 | - | - | 6,394 | ||
| Cashless exercise of warrants into common stock | 162,062 | -* | 20,621 | - | - | - | 20,621 | |
| Stock split adjustment | 909 | -* | -* | - | - | - | ||
| Balance as of March 31, 2025 (Unaudited) | 426,431 | $ | -* | $146,285 | $228 | $28 | $(139,283) | $7,258 |
| (*) | Represents amount lower than $1. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.